• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Lack of correlation between peripheral blood lymphokine-activated killer (LAK) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Ghosh, Anna K
    Dazzi, H
    Thatcher, Nick
    Moore, M
    Affiliation
    Cancer Research Campaign, Paterson Institute for Cancer Research, Christie Hospital, Manchester, UK.
    Issue Date
    1989-03-15
    
    Metadata
    Show full item record
    Abstract
    A phase-I/II study of recombinant interleukin 2 (rIL-2) was performed in 31 melanoma patients. The first dose of rIL-2 was given intrasplenically followed 4 hr later by an i.v. dose and 3 further i.v. doses on alternate days. Three courses of treatment were planned at 3-week intervals. The maximum tolerated single dose was 11 x 10(6) Cetus U/m2. Haematological and immunological data were available on 20 patients. Post-treatment response to rIL-2 therapy was evident from (i) a rapid depletion of peripheral blood lymphocytes (PBL) with a rebound at 4-7 days (2 times pre-treatment values); (ii) an increase in the number of IL-2 receptor-positive lymphocytes (4-15 times pre-treatment values); (iii) an increase in the number of "positive" patients with cytotoxic (anti-K562) peripheral blood mononuclear cells (PBMC) from 30% to 80%; (iv) amplified killing of K562 by positive patients in relation to pre-treatment values; and (v) the induction of PBMC cytotoxicity (in 45% of patients) against the NK-resistant, LAK-sensitive target, Mel I. Partial clinical responses to rIL-2 treatment were observed in 4 patients, but these were not reflected in the PBMC LAK activity or the other parameters examined.
    Citation
    Lack of correlation between peripheral blood lymphokine-activated killer (LAK) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2. 1989, 43 (3):410-4 Int. J. Cancer
    Journal
    International Journal of Cancer
    URI
    http://hdl.handle.net/10541/108136
    DOI
    10.1002/ijc.2910430311
    PubMed ID
    2784419
    Type
    Article
    Language
    en
    ISSN
    0020-7136
    ae974a485f413a2113503eed53cd6c53
    10.1002/ijc.2910430311
    Scopus Count
    Collections
    All Christie Publications
    All Paterson Institute for Cancer Research

    entitlement

    Related articles

    • Monocyte-dependent, serum-borne suppressor of induction of lymphokine-activated killer cells in lymphocytes from melanoma patients.
    • Authors: Itoh K, Pellis NR, Balch CM
    • Issue date: 1989
    • A phase II study of the administration of recombinant interleukin 2 (rIL-2) plus lymphokine activated killer (LAK) cells in stage IV melanoma patients.
    • Authors: Cascinelli N, Belli F, Marchini S, Marolda R, Prada A, Sciorelli G, Villani F, Gambacorti-Passerini C, Galazka A, Parmiani G
    • Issue date: 1989 Jun 30
    • In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2.
    • Authors: Schomburg A, Menzel T, Körfer A, Heer G, Dallmann I, Kirchner H, Poliwoda H, Atzpodien J
    • Issue date: 1992 May-Jun
    • In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy.
    • Authors: Klasa RJ, Silver HK, Kong S
    • Issue date: 1990 Aug 15
    • [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    • Authors: Saijo N, Ozaki A, Ishihara J, Sakurai M, Sasaki Y, Takahashi H, Sano T, Hoshi A
    • Issue date: 1986 Apr
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.